as 12-18-2024 10:44am EST
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 72.4M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 198.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.31 | EPS Growth: | N/A |
52 Week Low/High: | $2.38 - $5.86 | Next Earning Date: | 02-11-2025 |
Revenue: | $876,000 | Revenue Growth: | 8.08% |
Revenue Growth (this year): | -33.95% | Revenue Growth (next year): | -39.04% |
VTGN Breaking Stock News: Dive into VTGN Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
GuruFocus.com
a month ago
Zacks
a month ago
Business Wire
a month ago
GuruFocus.com
a month ago
Business Wire
a month ago
Business Wire
2 months ago
Zacks
2 months ago
The information presented on this page, "VTGN VistaGen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.